{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:20:59Z","timestamp":1790659259870,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.metabol.2024.155912","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:50:48Z","timestamp":1712796648000},"page":"155912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Deciphering the molecular pathways of saroglitazar: A dual PPAR \u03b1\/\u03b3 agonist for managing metabolic NAFLD"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5068-2383","authenticated-orcid":false,"given":"Devaraj","family":"Ezhilarasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.metabol.2024.155912_bb0005","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.155912_bb0010","doi-asserted-by":"crossref","first-page":"9233650","DOI":"10.1155\/2022\/9233650","article-title":"A molecular insight into the role of antioxidants in nonalcoholic fatty liver diseases","volume":"2022","author":"Ezhilarasan","year":"2022","journal-title":"Oxidative Med Cell Longev"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2024.155912_bb0020","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jceh.2022.12.011","article-title":"INASL-SAASL consensus statements on NAFLD name change to MAFLD","volume":"13","author":"Singh","year":"2023","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2024.155912_bb0025","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.155912_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155663","article-title":"Uroguanylin prevents hepatic steatosis, mitochondrial dysfunction and fibrosis in obesity-associated NAFLD","volume":"147","author":"Fern\u00e1ndez-S\u00e1ez","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155912_bb0035","doi-asserted-by":"crossref","first-page":"1087260","DOI":"10.3389\/fendo.2022.1087260","article-title":"Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)","volume":"13","author":"Rong","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.metabol.2024.155912_bb0040","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"suppl","key":"10.1016\/j.metabol.2024.155912_bb0045","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","article-title":"Non-alcoholic fatty liver disease: definition and subtypes","volume":"29","author":"Han","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"7","key":"10.1016\/j.metabol.2024.155912_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102174","article-title":"Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"47","author":"Bandyopadhyay","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"10.1016\/j.metabol.2024.155912_bb0555","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.metabol.2024.155912_bb0055","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.metabol.2024.155912_bb0060","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in Nonalcoholic fatty liver disease: revisited after a decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.metabol.2024.155912_bb0065","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"issue":"7698","key":"10.1016\/j.metabol.2024.155912_bb0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nature26138","article-title":"Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance","volume":"555","author":"Ghorpade","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2024.155912_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111315","article-title":"Adipose tissue and insulin resistance in obese","volume":"137","author":"Ahmed","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.metabol.2024.155912_bb0080","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jhep.2019.06.031","article-title":"Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease","volume":"71","author":"Rosso","year":"2019","journal-title":"J Hepatol"},{"issue":"18","key":"10.1016\/j.metabol.2024.155912_bb0085","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol Life Sci"},{"issue":"9","key":"10.1016\/j.metabol.2024.155912_bb0090","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death Dis"},{"issue":"12","key":"10.1016\/j.metabol.2024.155912_bb0095","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.2337\/db07-0907","article-title":"Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity","volume":"56","author":"Koonen","year":"2007","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.metabol.2024.155912_bb0100","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/en.2015-1866","article-title":"Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice","volume":"157","author":"Wilson","year":"2016","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.metabol.2024.155912_bb0105","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of nonalcoholic steatohepatitis: an overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.metabol.2024.155912_bb0110","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bbalip.2016.02.003","article-title":"Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5\u2019-UTR in a cellular model of hepatic steatosis","volume":"1861","author":"Siculella","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.metabol.2024.155912_bb0115","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.metabol.2024.155912_bb0120","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/cells9040837","article-title":"Role and mechanisms of mitophagy in liver diseases","volume":"9","author":"Ma","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.metabol.2024.155912_bb0125","article-title":"Mitochondrial dysfunction: a promising therapeutic target for liver diseases","volume":"11","author":"Chen","year":"2023","journal-title":"Genes Dis"},{"key":"10.1016\/j.metabol.2024.155912_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2020.102336","article-title":"Role of mitochondria in liver metabolic health and diseases","volume":"94","author":"Morio","year":"2021","journal-title":"Cell Calcium"},{"key":"10.1016\/j.metabol.2024.155912_bb0135","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fphys.2014.00282","article-title":"Mitochondrial and cellular mechanisms for managing lipid excess","volume":"5","author":"Aon","year":"2014","journal-title":"Front Physiol"},{"issue":"13","key":"10.1016\/j.metabol.2024.155912_bb0140","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.3390\/ijms22136949","article-title":"Mitochondrial lipid homeostasis at the crossroads of liver and heart diseases","volume":"22","author":"Dabravolski","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.metabol.2024.155912_bb0145","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/antiox11050801","article-title":"Mitochondrial calcium: effects of its imbalance in disease","volume":"11","author":"Matuz-Mares","year":"2022","journal-title":"Antioxidants (Basel)"},{"issue":"7","key":"10.1016\/j.metabol.2024.155912_bb0150","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.3390\/cimb44070218","article-title":"Mitochondrial dysfunction and chronic liver disease","volume":"44","author":"Zhang","year":"2022","journal-title":"Curr Issues Mol Biol"},{"issue":"11","key":"10.1016\/j.metabol.2024.155912_bb0155","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1002\/bit.27901","article-title":"Enhanced ammonia detoxification to urea in hepatocytes transduced with human aquaporin-8 gene","volume":"118","author":"Capiglioni","year":"2021","journal-title":"Biotechnol Bioeng"},{"issue":"7","key":"10.1016\/j.metabol.2024.155912_bb0160","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.31557\/APJCP.2020.21.7.1877","article-title":"Silibinin triggers the mitochondrial pathway of apoptosis in human oral squamous carcinoma cells","volume":"21","author":"Murali Iyangar","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"10.1016\/j.metabol.2024.155912_bb0165","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041038","article-title":"The mitochondrial pathway of apoptosis: part I: MOMP and beyond","volume":"14","author":"Green","year":"2022","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.metabol.2024.155912_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101122","article-title":"Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans","volume":"50","author":"Pafili","year":"2021","journal-title":"Mol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2024.155912_bb0175","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3390\/biom12060824","article-title":"NAFLD: mechanisms, treatments, and biomarkers","volume":"12","author":"Nassir","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3350\/cmh.2022.0237","article-title":"Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.155912_bb0185","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.hbpd.2021.04.010","article-title":"Mitochondria: a critical hub for hepatic stellate cells activation during chronic liver diseases","volume":"20","author":"Ezhilarasan","year":"2021","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.metabol.2024.155912_bb0190","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mito.2020.12.010","article-title":"Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"57","author":"Ajaz","year":"2021","journal-title":"Mitochondrion"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","article-title":"Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it","volume":"6","author":"Begriche","year":"2006","journal-title":"Mitochondrion"},{"issue":"4","key":"10.1016\/j.metabol.2024.155912_bb0200","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.26226","article-title":"Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease","volume":"58","author":"Begriche","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.metabol.2024.155912_bb0205","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.metabol.2024.155912_bb0210","doi-asserted-by":"crossref","first-page":"G193","DOI":"10.1152\/ajpgi.00426.2001","article-title":"Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis","volume":"282","author":"Pessayre","year":"2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"10.1016\/j.metabol.2024.155912_bb0215","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tem.2016.11.006","article-title":"Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies","volume":"28","author":"Sunny","year":"2017","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jceh.2012.10.009","article-title":"Patients with nonalcoholic fatty liver disease (NAFLD) have higher oxidative stress in comparison to chronic viral hepatitis","volume":"3","author":"Kumar","year":"2013","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.metabol.2024.155912_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101710","article-title":"Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis","volume":"37","author":"Podszun","year":"2020","journal-title":"Redox Biol"},{"key":"10.1016\/j.metabol.2024.155912_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154708","article-title":"Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?","volume":"117","author":"Longo","year":"2021","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.metabol.2024.155912_bb0235","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/jcm10040792","article-title":"Roles of ceramides in non-alcoholic fatty liver disease","volume":"10","author":"Hajduch","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.metabol.2024.155912_bb0240","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jhep.2018.06.008","article-title":"Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease","volume":"69","author":"Lebeaupin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.155912_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105218","article-title":"Endoplasmic reticulum stress and protein degradation in chronic liver disease","volume":"161","author":"Xia","year":"2020","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.metabol.2024.155912_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166097","article-title":"PPARs in liver physiology","volume":"1867","author":"Berthier","year":"2021","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"issue":"4","key":"10.1016\/j.metabol.2024.155912_bb0255","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3390\/ijms19040949","article-title":"Pivotal roles of peroxisome proliferator-activated receptors (PPARs) and their signal cascade for cellular and whole-body energy homeostasis","volume":"19","author":"Lamichane","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0260","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7150\/ijbs.87305","article-title":"The role of nuclear receptors in the pathogenesis and treatment of non-alcoholic fatty liver disease","volume":"20","author":"Yang","year":"2024","journal-title":"Int J Biol Sci"},{"issue":"7","key":"10.1016\/j.metabol.2024.155912_bb0265","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3390\/cells9071638","article-title":"Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease","volume":"9","author":"Fougerat","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.metabol.2024.155912_bb0270","doi-asserted-by":"crossref","unstructured":"Grygiel-G\u00f3rniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications-a review. Nutr J 2014;13:17.","DOI":"10.1186\/1475-2891-13-17"},{"issue":"6","key":"10.1016\/j.metabol.2024.155912_bb0275","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3390\/ijms21062061","article-title":"PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice","volume":"21","author":"Wang","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"14","key":"10.1016\/j.metabol.2024.155912_bb0280","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.3390\/molecules24142545","article-title":"PPARs as nuclear receptors for nutrient and energy metabolism","volume":"24","author":"Hong","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.metabol.2024.155912_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154338","article-title":"The role of peroxisome proliferator-activated receptors (PPAR) in immune responses","volume":"114","author":"Christofides","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155912_bb0290","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2020.00730","article-title":"Peroxisome proliferator-activated receptors: experimental targeting for the treatment of inflammatory bowel diseases","volume":"11","author":"Decara","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.metabol.2024.155912_bb0295","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cmet.2017.03.011","article-title":"PPARgamma links BMP2 and TGFbeta1 pathways in vascular smooth muscle cells, regulating cell proliferation and glucose metabolism","volume":"25","author":"Calvier","year":"2017","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0300","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1499-3872(11)60009-X","article-title":"Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats","volume":"10","author":"Wang","year":"2011","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"49","key":"10.1016\/j.metabol.2024.155912_bb0305","doi-asserted-by":"crossref","first-page":"40650","DOI":"10.1074\/jbc.M510094200","article-title":"Peroxisome proliferator-activated receptor gamma suppresses proximal alpha1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells","volume":"280","author":"Yavrom","year":"2005","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0310","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cgh.2021.12.044","article-title":"Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor\/firsocostat","volume":"21","author":"Lawitz","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.155912_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154798","article-title":"Fenofibrate, a PPAR\u03b1 agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy","volume":"120","author":"Yoo","year":"2021","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.metabol.2024.155912_bb0320","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2024.155912_bb0325","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/13894501113149990199","article-title":"The first approved agent in the Glitazar\u2019s class: Saroglitazar","volume":"15","author":"Agrawal","year":"2014","journal-title":"Curr Drug Targets"},{"issue":"9","key":"10.1016\/j.metabol.2024.155912_bb0330","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1248\/bpb.b21-00232","article-title":"Structural basis for anti-non-alcoholic fatty liver disease and diabetic dyslipidemia drug Saroglitazar as a PPAR \u03b1\/\u03b3 dual agonist","volume":"44","author":"Honda","year":"2021","journal-title":"Biol Pharm Bull"},{"issue":"12","key":"10.1016\/j.metabol.2024.155912_bb0335","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A phase 2 double blinded, randomized controlled trial of Saroglitazar in patients with nonalcoholic steatohepatitis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2024.155912_bb0340","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.136","article-title":"Saroglitazar, a novel PPAR\u03b1\/\u03b3 agonist with predominant PPAR\u03b1 activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models","volume":"3","author":"Jain","year":"2015","journal-title":"Pharmacol Res Perspect"},{"issue":"11","key":"10.1016\/j.metabol.2024.155912_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22051","article-title":"Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL\/6J mice","volume":"9","author":"Kumari","year":"2023","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.metabol.2024.155912_bb0350","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.metabol.2024.155912_bb0355","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s10753-019-00967-6","article-title":"Saroglitazar deactivates the hepatic LPS\/TLR4 signaling pathway and ameliorates adipocyte dysfunction in rats with high-fat emulsion\/LPS model-induced non-alcoholic steatohepatitis","volume":"42","author":"Hassan","year":"2019","journal-title":"Inflammation"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0360","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR \u03b1\/\u03b3 agonist Saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2024.155912_bb0365","doi-asserted-by":"crossref","first-page":"1378175","DOI":"10.1155\/2017\/1378175","article-title":"Collaborative power of Nrf2 and PPAR\u03b3 activators against metabolic and drug-induced oxidative injury","volume":"2017","author":"Lee","year":"2017","journal-title":"Oxidative Med Cell Longev"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0370","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40360-021-00524-8","article-title":"Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis","volume":"22","author":"Akbari","year":"2021","journal-title":"BMC Pharmacol Toxicol"},{"issue":"19","key":"10.1016\/j.metabol.2024.155912_bb0375","doi-asserted-by":"crossref","first-page":"10431","DOI":"10.3390\/ijms221910431","article-title":"PPAR\u03b3 and TGF\u03b2-major regulators of metabolism, inflammation, and fibrosis in the lungs and kidneys","volume":"22","author":"K\u00f6k\u00e9ny","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.metabol.2024.155912_bb0380","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1745-7254.2006.00299.x","article-title":"PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression","volume":"27","author":"Sun","year":"2006","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0385","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/aps.2009.174","article-title":"PPARgamma agonists inhibit TGF-beta-PKA signaling in glomerulosclerosis","volume":"31","author":"Zou","year":"2010","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.metabol.2024.155912_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112357","article-title":"Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids","volume":"144","author":"Sarkar","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0395","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12885-023-10530-0","article-title":"Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL\/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet","volume":"23","author":"Giri","year":"2023","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.metabol.2024.155912_bb0400","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/dia.2013.0253","volume":"16","author":"Jani","year":"2014","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0405","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1932296813518680","article-title":"A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V)","volume":"8","author":"Pai","year":"2014","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0410","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ihj.2015.02.007","article-title":"Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients","volume":"67","author":"Shetty","year":"2015","journal-title":"Indian Heart J"},{"key":"10.1016\/j.metabol.2024.155912_bb0415","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/DMSO.S49592","article-title":"Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence","volume":"8","author":"Sosale","year":"2015","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.metabol.2024.155912_bb0420","doi-asserted-by":"crossref","first-page":"4287075","DOI":"10.1155\/2020\/4287075","article-title":"Clinical case series of decrease in shear wave elastography values in ten diabetic dyslipidemia patients having NAFLD with Saroglitazar 4mg: an Indian experience","volume":"2020","author":"Roy","year":"2020","journal-title":"Case Rep Med"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0425","doi-asserted-by":"crossref","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real-world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0430","first-page":"97","article-title":"Saroglitazar improves transaminases and elastography in patients with diabetic dyslipidemia and non-alcoholic fatty liver disease","volume":"68","author":"Goyal","year":"2020","journal-title":"J Assoc Physicians India"},{"issue":"7","key":"10.1016\/j.metabol.2024.155912_bb0435","article-title":"An observational study of reduction in glycemic parameters and liver stiffness by Saroglitazar 4 mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"12","author":"Mitra","year":"2020","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.metabol.2024.155912_bb0440","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0445","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jceh.2021.03.012","article-title":"Safety and efficacy of Saroglitazar in Nonalcoholic fatty liver patients with diabetic dyslipidemia-a prospective, interventional","volume":"12","author":"Rajesh","year":"2022","journal-title":"Pilot Study J Clin Exp Hepatol"},{"issue":"2","key":"10.1016\/j.metabol.2024.155912_bb0450","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jceh.2021.06.015","article-title":"Saroglitazar for nonalcoholic fatty liver disease: a single centre experience in 91 patients","volume":"12","author":"Padole","year":"2022","journal-title":"J Clin Exp Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2024.155912_bb0455","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jgh3.12878","article-title":"Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: a tertiary care center experience","volume":"7","author":"Chaudhuri","year":"2023","journal-title":"JGH Open"},{"key":"10.1016\/j.metabol.2024.155912_bb0460","doi-asserted-by":"crossref","DOI":"10.1097\/LVT.0000000000000110","article-title":"Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients","author":"Siddiqui","year":"2023","journal-title":"Liver Transpl"},{"key":"10.1016\/j.metabol.2024.155912_bb0465","unstructured":"Siddiqui MS, Parmar D, Sheikh F, et al. Saroglitazar, a dual PPAR \u03b1\/\u03b3 agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis. Clin Gastroenterol Hepatol 2023b:S1542-3565(23)00077\u20130."},{"key":"10.1016\/j.metabol.2024.155912_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155759","article-title":"Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLD","volume":"151","author":"Bilson","year":"2024","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0475","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1080\/07853890.2023.2179106","article-title":"Adiponectin-leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance","volume":"55","author":"Lu","year":"2023","journal-title":"Ann Med"},{"issue":"3","key":"10.1016\/j.metabol.2024.155912_bb0480","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1194\/jlr.M081836","article-title":"Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice","volume":"59","author":"Linden","year":"2018","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.metabol.2024.155912_bb0485","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ajg.2018.03.002","article-title":"Oxidative stress is bane in chronic liver diseases: clinical and experimental perspective","volume":"19","author":"Ezhilarasan","year":"2018","journal-title":"Arab J Gastroenterol"},{"key":"10.1016\/j.metabol.2024.155912_bb0490","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2119\/molmed.2016.00203","article-title":"Induction of steatohepatitis (NASH) with insulin resistance in wildtype B6 mice by a western-type diet containing soybean oil and cholesterol","volume":"23","author":"Henkel","year":"2017","journal-title":"Mol Med"},{"issue":"5","key":"10.1016\/j.metabol.2024.155912_bb0495","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41388-023-02907-z","article-title":"ROS production by mitochondria: function or dysfunction?","volume":"43","author":"Palma","year":"2024","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.metabol.2024.155912_bb0500","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3390\/nu10091326","article-title":"Soybean oil-derived poly-unsaturated fatty acids enhance liver damage in NAFLD induced by dietary cholesterol","volume":"10","author":"Henkel","year":"2018","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.metabol.2024.155912_bb0505","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/nu11040872","article-title":"Oxidative stress and non-alcoholic fatty liver disease: effects of Omega-3 fatty acid supplementation","volume":"11","author":"Yang","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.metabol.2024.155912_bb0510","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bcp.2017.04.014","article-title":"Apigenin, a modulator of PPAR\u03b3, attenuates HFD-induced NAFLD by regulating hepatocyte lipid metabolism and oxidative stress via Nrf2 activation","volume":"136","author":"Feng","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.metabol.2024.155912_bb0515","article-title":"Saroglitazar, a dual PPAR-\u03b1\/\u03b3 agonist, alleviates LPS-induced hepatic and renal injury in rats","volume":"115","author":"Francis","year":"2023","journal-title":"Int Immuno Pharmacol"},{"key":"10.1016\/j.metabol.2024.155912_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.etap.2021.103755","article-title":"Deciphering the toxicological role of Porphyromonas gingivalis derived endotoxins in liver diseases","volume":"88","author":"Ezhilarasan","year":"2021","journal-title":"Environ Toxicol Pharmacol"},{"issue":"2","key":"10.1016\/j.metabol.2024.155912_bb0525","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hep.31056","article-title":"Increased liver localization of lipopolysaccharides in human and experimental NAFLD","volume":"72","author":"Carpino","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.metabol.2024.155912_bb0530","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3164\/jcbn.13-49","article-title":"Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats","volume":"54","author":"Fukunishi","year":"2014","journal-title":"J Clin Biochem Nutr"},{"issue":"12","key":"10.1016\/j.metabol.2024.155912_bb0535","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1111\/liv.15441","article-title":"Regulation of the macrophage-hepatic stellate cell interaction by targeting macrophage peroxisome proliferator-activated receptor gamma to prevent non-alcoholic steatohepatitis progression in mice","volume":"42","author":"Ni","year":"2022","journal-title":"Liver Int"},{"issue":"20","key":"10.1016\/j.metabol.2024.155912_bb0540","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.3390\/ijms20205055","article-title":"Exploration and development of PPAR modulators in health and disease: an update of clinical evidence","volume":"20","author":"Cheng","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.metabol.2024.155912_bb0545","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.dsx.2020.08.039","article-title":"Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: a meta-analysis","volume":"14","author":"Dutta","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.metabol.2024.155912_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.599995","article-title":"PPAR-\u03b1 modulators as current and potential cancer treatments","volume":"11","author":"Tan","year":"2021","journal-title":"Front Oncol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524001380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524001380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T17:21:34Z","timestamp":1715188894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524001380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":111,"alternative-id":["S0026049524001380"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.155912","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deciphering the molecular pathways of saroglitazar: A dual PPAR \u03b1\/\u03b3 agonist for managing metabolic NAFLD","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.155912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155912"}}